Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

Phase II Study Meets Primary Bone Mineral Density and Secondary Efficacy Endpoints Company to Host Conference Call and Webcast

SAN DIEGO, Sept 02, 2008 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc. (NBIX:5.49, -0.12, -2.1%) today announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment.


http://www.marketwatch.com/news/story/neurocrine-biosciences-announces-successful-elagolix/story.aspx?guid=%7B3879911C-9A9C-49C0-862C-9A8FCCADF7FF%7D&dist=hppr